Charles Schwab Investment Management Inc. purchased a new position in shares of Inhibrx, Inc. (NASDAQ:INBX - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 32,657 shares of the company's stock, valued at approximately $503,000. Charles Schwab Investment Management Inc. owned about 0.23% of Inhibrx as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other hedge funds have also bought and sold shares of INBX. Exchange Traded Concepts LLC bought a new position in Inhibrx during the 4th quarter worth approximately $148,000. Empirical Financial Services LLC d.b.a. Empirical Wealth Management bought a new position in Inhibrx during the fourth quarter worth $348,000. China Universal Asset Management Co. Ltd. bought a new position in Inhibrx during the fourth quarter worth $47,000. Rhumbline Advisers acquired a new position in Inhibrx in the fourth quarter worth $228,000. Finally, New York State Common Retirement Fund bought a new stake in Inhibrx during the fourth quarter valued at $53,000. 82.46% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
Separately, JMP Securities restated a "market perform" rating on shares of Inhibrx in a research report on Wednesday, January 22nd.
Check Out Our Latest Research Report on Inhibrx
Inhibrx Stock Performance
INBX stock traded up $0.01 during midday trading on Friday, reaching $13.34. The company had a trading volume of 270,761 shares, compared to its average volume of 215,331. The stock has a 50 day moving average price of $13.39 and a 200 day moving average price of $14.51. Inhibrx, Inc. has a fifty-two week low of $10.80 and a fifty-two week high of $35.42.
Inhibrx (NASDAQ:INBX - Get Free Report) last announced its quarterly earnings results on Monday, March 17th. The company reported ($3.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.88) by ($0.21). The company had revenue of $0.10 million during the quarter. As a group, analysts anticipate that Inhibrx, Inc. will post 104.88 EPS for the current year.
Inhibrx Profile
(
Free Report)
Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.
Recommended Stories
Before you consider Inhibrx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inhibrx wasn't on the list.
While Inhibrx currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
